End-stage kidney diseaseDefinition:
End-stage kidney disease is the complete, or almost complete failure of the kidneys to function. The main function of the kidneys is to remove wastes and excess water from the body.
Renal failure - end stage; Kidney failure - end stage; ESRD
Causes, incidence, and risk factors:
End-stage kidney disease (ESRD) occurs when the kidneys are no longer able to function at a level needed for day-to-day life. It usually occurs when chronic kidney disease has worsened to the point at which kidney function is less than 10% of normal.
ESRD almost always follows chronic kidney disease. A person may have gradual worsening of kidney function for 10 - 20 years or more before progressing to ESRD.
Patients who have reached this stage need dialysis or a kidney transplant .
The most common causes of ESRD in the U.S. are diabetes and high blood pressure . See Chronic kidney disease for a complete list of causes.
Symptoms may include:
Other symptoms may develop, including:
- Abnormally dark or light skin and changes in nails
- Bone pain
- Brain and nervous system symptoms
- Breath odor
- Easy bruising, nosebleeds, or blood in the stool
- Excessive thirst
- Frequent hiccups
- Low level of sexual interest and impotence
- Menstrual periods stop (amenorrhea )
- Sleep problems, such as insomnia , restless leg syndrome , or obstructive sleep apnea
- Swelling of the feet and hands (edema )
Vomiting , especially in the morning
Signs and tests:
High blood pressure almost always occurs during end-stage kidney disease. A brain and nervous system (neurologic) examination may show signs of nerve damage. The health care provider may hear abnormal heart or lung sounds with a stethoscope.
Patients with end-stage kidney disease will make much less urine, or urine production may stop.
End-stage kidney disease changes the results of many tests. Patients receiving dialysis will need these and other tests done often:
This disease may also change the results of the following tests:
Dialysis or kidney transplantation is the only treatment for ESRD.
You should begin to prepare for dialysis before it is absolutely necessary. The preparation includes learning about dialysis and the types of dialysis therapies, and placement of a dialysis access.
Treatment usually includes an ACE inhibitor, angiotensin receptor blocker, or other medications for high blood pressure.
You may need to make changes in your diet.
- Eat a low-protein diet
- Get enough calories if you are losing weight
- Limit fluids
- Limit salt, potassium, phosphorous, and other electrolytes
See Diet and chronic kidney disease for more detail.
Other treatments may include:
- Extra calcium and vitamin D (always talk to your doctor before taking)
- Special medicines called phosphate binders, to help prevent phosphorous levels from becoming too high
- Treatment for anemia, such as extra iron in the diet, iron pills, special shots of a medicine called erythropoietin, and blood transfusions.
Different treatments are available for problems with sleep or restless leg syndrome.
Patients with chronic kidney disease should be up-to-date on important vaccinations, including:
Without dialysis or a kidney transplant, death will occur from the buildup of fluids and waste products in the body. Both of these treatments can have serious risks and consequences. The outcome is different for each person.
- Bleeding from the stomach or intestines
- Bone, joint, and muscle pain
- Brain dysfunction, confusion, and dementia
- Changes in electrolyte levels
- Changes in blood sugar (glucose)
Damage to nerves of the legs and arms
Fluid buildup around the lungs
- Heart and blood vessel complications
Hepatitis B , hepatitis C , liver failure
- Increased risk of infections
- Phosphorous levels become too high
Potassium levels become too high
- Skin dryness, itching/scratching, leading to skin infection
- Weakening of the bones, fractures, joint disorders
Treatment of chronic kidney disease may delay or prevent progression to ESRD. Some cases may not be preventable.
Tolkoff-Rubin N. Treatment of irreversible renal failure. In: Goldman L, Ausiello D, eds. Goldman: Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 133.
Mitch WE. Chronic kidney disease. In: Goldman L, Ausiello D, eds. Goldman: Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 131.
KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
KDOQI: National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16-S85.
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-S290.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.
|Review Date: 8/31/2010|
Reviewed By: Charles Silberberg, DO, Private Practice specializing in Nephrology, Affiliated with New York Medical College, Division of Nephrology, Valhalla, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.